Skip to content

Iron Overload and Endocrinological Diseases

Iron Overload and Endocrinological Diseases

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06137079
Enrollment
62
Registered
2023-11-18
Start date
2013-06-20
Completion date
2025-12-31
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endocrinopathy, Hemochromatosis, Iron Overload, Thalassemia Intermedia, Thalassemia Major

Brief summary

Patients with hemochromatosis or Thalassemia develop progressive tissue and organs damages secondary to iron overload. Iron overload can result both from transfusional hemosiderosis and excess gastrointestinal iron absorption. Iron deposition in the heart, liver, and multiple endocrine glands results in severe damage to these organs, with variable degrees of endocrine and organ failure. Although patients with iron overload often present endocrine disorders, the pathogenetic mechanisms underlying endocrinopathies are not completely clear. In particular it is not elucidated if the spectrum of endocrinopathies could change with advancing age. All endocrinological comorbidities can develop from a primary damage of the target gland, from pituitary secondary failure or from both. The aim of this study is to investigate the prevalence of endocrinological diseases in adult patients with iron overload due to β-thalassemia or hemochromatosis and their impact on well-being and quality of life. The study design is a prospective cross-sectional clinical study. All subjects enrolled will be evaluated for the endocrine diseases. The study protocol will include data collection from family and patients' history of diseases, physical examination, hormonal assessment for all endocrine axes and instrumental examinations. The results will provide evidence on the prevalence of endocrine diseases in patients with iron overload and will add information to characterize the type and the degree of endocrine deficiencies, and on the pathogenic mechanisms involved, in order to individualize diagnostic and therapeutic approaches.

Interventions

None listed

Sponsors

Azienda Ospedaliero-Universitaria di Modena
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Certain diagnosis of β-thalassemia major or intermedia * Certain diagnosis of Hereditary Hemochromatosis * Adult patients with an age between 18 and 65 years

Exclusion criteria

* Subjects with an age \< 18 and \> 65 years

Design outcomes

Primary

MeasureTime frame
Estimate prevalence of endocrine comorbidities of β-thalassemia in adulthood12 years

Secondary

MeasureTime frame
Evaluate prevalence of endocrine diseases to characterize the type and the degree of endocrine deficiencies12 years
Evaluate incidence of endocrine diseases to characterize the type and the degree of endocrine deficiencies12 years
To investigate the relationships among iron status and endocrine alterations in these group of patients12 years
To investigate the relationships among iron status and cardiac disease in these group of patients12 years
To investigate the relationships among iron status and liver disease in these group of patients12 years

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026